Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lung cancer RFA (radiofrequency ablation) results boost shares in Rita Medical

This article was originally published in Clinica

Executive Summary

Shares in US-based Rita Medical Systems soared by nearly 30% last week, after the company reported positive data from a trial of its radiofrequency ablation (RFA) treatment for lung cancer. 18-month survival statistics from the study, presented at the Radiological Society of North America (RSNA), in Chicago, showed the RFA technique to be feasible in 99% of the 106 lung cancer patients who took part in the study.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel